NanoViricides provides update on development program for NV-387

NanoViricides discussed its development program for NV-387, a single drug that has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications. There are several viruses that continue to cause epidemics in humans; seasonal epidemics with Influenza, RSV, and SARS-CoV-2 are occurring every year. The company said the potential for severe Bird Flu pandemic, that may even be worse than the COVID-19 outbreak, is increasing every year as the virus spreads further into mammals and mutates more, according to experts. Recently a fifth human case of H5Nx “Bird Flu” infection in the USA, acquired at work with infected dairy cattle, was found in Colorado. The person exhibited conjunctivitis symptoms, was given Tamiflu, and has recovered, according to the Colorado Department of Public Health and Environment, or CDPHE. The risk to humans in general remains low, because this bird flu virus has not yet acquired the ability for human-to-human transmission, according to scientists. However, H5N1 bird flu is now widespread in wild birds, and has infected and spread in many mammals, including dairy cattle. The company said, “We have started planning Phase II clinical studies of NV-387 as a treatment for RSV and other indications including Influenza and COVID, as the Phase I clinical trial comes to a close. We plan on taking the drug NV-387 forward on the fastest regulatory path feasible towards regulatory approvals in different countries and jurisdictions including the USA.”